Scarica l'app Stockscreener
10.83
24.04%
2.0474
Precedente Chiudi:
$8.78
Aprire:
$12.2
Volume 24 ore:
17.68M
Relative Volume:
18.60
Capitalizzazione di mercato:
$474.75M
Reddito:
-
Utile/perdita netta:
$-110.66M
Rapporto P/E:
-3.4969
EPS:
-3.0963
Flusso di cassa netto:
$-97.76M
1 W Prestazione:
+31.69%
1M Prestazione:
+58.29%
6M Prestazione:
+238.22%
1 anno Prestazione:
+146.39%
Intervallo 1D:
$10.40
$13.67
Intervallo di 1 settimana:
$7.80
$13.67
Portata 52W:
$1.78
$13.67
Kyverna Therapeutics Inc Stock (KYTX) Company Profile
Nome
Kyverna Therapeutics Inc
Settore
Industria
Telefono
(510) 626-8331
Indirizzo
5980 HORTON STREET, EMERYVILLE
Confronta KYTX con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
KYTX
Kyverna Therapeutics Inc
|
10.84 | 384.53M | 0 | -110.66M | -97.76M | -3.0963 |
|
VRTX
Vertex Pharmaceuticals Inc
|
453.50 | 114.69B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
755.39 | 77.91B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
846.16 | 54.05B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
394.74 | 52.52B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
196.59 | 42.02B | 447.02M | -1.18B | -906.14M | -6.1812 |
Kyverna Therapeutics Inc Stock (KYTX) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-08-20 | Iniziato | William Blair | Outperform |
| 2025-05-27 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2024-10-10 | Iniziato | UBS | Buy |
| 2024-10-09 | Iniziato | Rodman & Renshaw | Buy |
| 2024-07-03 | Iniziato | H.C. Wainwright | Neutral |
| 2024-03-04 | Iniziato | JP Morgan | Overweight |
| 2024-03-04 | Iniziato | Leerink Partners | Outperform |
| 2024-03-04 | Iniziato | Morgan Stanley | Overweight |
| 2024-03-04 | Iniziato | Wells Fargo | Overweight |
Mostra tutto
Kyverna Therapeutics Inc Borsa (KYTX) Ultime notizie
KYTX Stock Skyrockets: Investors Take Notice - timothysykes.com
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks making the biggest moves today - MSN
Tesla, iRobot, ServiceNow, Radiopharm Theranostics, Kyverna Therapeutics: Stocks Making The Biggest Moves Today - Stocktwits
Kyverna Therapeutics: Miv-Cel Delivers Breakthrough Data In Stiff Person Syndrome (KYTX) - Seeking Alpha
Kyverna Therapeutics (NASDAQ:KYTX) Hits New 12-Month HighStill a Buy? - MarketBeat
Kyverna to take autoimmune CAR-T to FDA after success in stiff person syndrome trial - Endpoints News
'Unprecedented' data prime Kyverna for 1st autoimmune CAR-T drug - Fierce Biotech
Kyverna Therapeutics Sees Unusually High Options Volume (NASDAQ:KYTX) - MarketBeat
Kyverna shares spike as CAR-T hits endpoints in stiff person syndrome - FirstWord Pharma
Kyverna Therapeutics announces topline data from registrational KYSA-8 trial - TipRanks
Can Kyverna Therapeutics Stock Surge Further? - StocksToTrade
Kyverna to seek first clearance of a CAR-T therapy for autoimmune disease - BioPharma Dive
Kyverna Therapeutics Inc. (KYTX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Why Is Kyverna Therapeutics Stock Skyrocketing Monday?Kyverna Therapeutics (NASDAQ:KYTX) - Benzinga
Kyverna rises on stiff person syndrome data - pharmaphorum
Kyverna Reports Positive Phase 2 Trial Results - TipRanks
Kyverna shares jump on strong results from SPS clinical trial - MSN
KYTX Stock Just Surged 11% Today – What Is The Connection With Stiff Person Syndrome? - Stocktwits
Kyverna Shares Surge on Strong Topline Results From Phase 2 SPS Trial - Tokenist
Kyverna Therapeutics stock soars after positive SPS trial data By Investing.com - Investing.com UK
Kyverna Therapeutics stock soars after positive SPS trial data - Investing.com
KYTX stock just surged 11% today – what is the connection with stiff person syndrome? - MSN
KYTX: Miv-cel achieved robust efficacy and safety in SPS, supporting a 2026 FDA submission - TradingView — Track All Markets
Kyverna Therapeutics Reports Positive Phase 2 Trial Results - TipRanks
Kyverna jumps after cell therapy meets main goal of mid-stage study - TradingView — Track All Markets
Kyverna's cell therapy meets main goal of mid-stage study - TradingView — Track All Markets
Kyverna Therapeutics shares surge 24% premarket after positive trial data - marketscreener.com
Kyverna Therapeutics Announces Positive Topline Data From Registrational Kysa-8 Trial Of Miv-Cel (Kyv-101) In Stiff Person Syndrome - TradingView — Track All Markets
Kyverna Therapeutics Announces Positive Topline Data from KYSA-8 Trial - TradingView — Track All Markets
Kyverna Therapeutics Announces Positive Topline Data from Registrational KYSA-8 Trial of ... - Bakersfield.com
Kyverna (Nasdaq: KYTX) SPS CAR-T meets Phase 2 goals, plans 1H 2026 BLA filing - Stock Titan
Kyverna Therapeutics Inc Stock Analysis and ForecastSector Rotation Strategies & Free Stock Chart Pattern Guides - earlytimes.in
2 'strong buy' biotech stocks with 208% to 329% upside potential - MSN
Kyverna to present topline results from Phase 2 trial in stiff person syndrome - Investing.com
Kyverna Therapeutics to Present Topline Results from Phase 2 KYSA-8 Clinical Trial for KYV-101 in Stiff Person Syndrome - Quiver Quantitative
Kyverna Therapeutics to Report Topline Results from Registrational Phase 2 KYSA-8 Trial of KYV-101 in Stiff Person Syndrome - The Manila Times
Kyverna Therapeutics to Report Topline Results from - GlobeNewswire
Kyverna Therapeutics (NASDAQ:KYTX) Upgraded to Hold at Wall Street Zen - MarketBeat
Palmetto Grain Brokerage - Palmetto Grain Brokerage
2 ‘Strong Buy’ Biotech Stocks With 208% to 329% Upside Potential - Barchart.com
Momentum Shift: What is the fair value of Kyverna Therapeutics Inc stock now2025 Market Overview & Smart Swing Trading Alerts - moha.gov.vn
Kyverna Therapeutics, Inc. (NASDAQ:KYTX) Receives Average Recommendation of "Moderate Buy" from Analysts - MarketBeat
Morgan Stanley maintains Kyverna Therapeutics (KYTX) overweight recommendation - MSN
Kyverna Therapeutics price target raised to $25 from $20 at Morgan Stanley - TipRanks
Why analysts remain bullish on Kyverna Therapeutics Inc. stockMarket Growth Report & Stepwise Entry/Exit Trade Alerts - Newser
Published on: 2025-12-04 05:07:23 - Newser
How institutional buying supports Kyverna Therapeutics Inc. stock2025 Market Outlook & Risk Managed Investment Strategies - Newser
Kyverna Therapeutics (KYTX) Stock Analysis Report | Financials & Insights - Benzinga
IPO Launch: Will Kyverna Therapeutics Inc stock recover faster than peersJuly 2025 Momentum & AI Optimized Trade Strategies - BỘ NỘI VỤ
HC Wainwright & Co. Maintains Kyverna Therapeutics (KYTX) Buy Recommendation - MSN
6 Companies Hanging On in Cell Therapy - BioSpace
Kyverna Therapeutics Inc Azioni (KYTX) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
0.56%
1.23%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):